Retreatment for HCV may require switching DAA inhibitor classes

Patients who failed to achieve sustained virologic response after initial treatment for hepatitis C achieved high cure rates during retreatment after switching from an NS5A inhibitor direct-acting antiviral to a protease inhibitor.“The management of DAA failure patients remains a challenge,” Julia Dietz, MD, from the Goethe University Hospital in Frankfurt, Germany, and colleagues wrote. They highlighted the fact that many patients develop resistance associated substitutions (RASs), particularly NS5A RASs, and there remains limited data on retreatment success.To analyze theRead More

Share on facebook
Share on twitter
Share on linkedin